Covid-19 Archives

Startup Scout 29 Sep 2022

Baseimmune makes future-proof vaccines with AI

Baseimmune is using artificial intelligence (AI) to design vaccines that can protect against future variants of infectious diseases including COVID-19 and malaria. Big data has taken off in the last decade, with dramatic improvements in bioinformatics, data science and AI. These advances allow researchers to store and handle more and more data generated by research […]

September 29, 2022 - 6 minutesmins - By Jonathan Smith

News and Trends 26 Sep 2022

Cuba to receive €46.7M to boost biopharma sector

The Central American Bank for Economic Integration (CABEI) has signed the first financing agreement with the Republic of Cuba for the execution of a project to strengthen the Cuban biopharmaceutical industry. On of the goals of the project is to combat COVID-19. The funding is for a total of €46.7 million ($45 million). The initiative, […]

September 26, 2022 - 2 minutesmins - By Jim Cornall

News and Trends 14 Sep 2022

New study reveals first genetic links in ME and chronic fatigue syndrome

For the first time in more than 30 years, replicable genetic findings have been reported in the study into myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). UK-based PrecisionLife today (September 14) unveiled the results offering new approaches for better diagnosis and treatments of patients. The data has also been submitted for peer reviewed publication and is available […]

September 14, 2022 - 3 minutesmins - By Liza Laws

News and Trends 8 Sep 2022

Investment of €130M made by Merck’s MilliporeSigma for life-saving therapies

An investment of €130 million ($130 million) has been invested in Molsheim, France to strengthen manufacturing capabilities for single-use assemblies – a key technology for the production of Covid-19 vaccines and other life-saving therapies. The investment was made by MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA. It is the largest ever […]

September 8, 2022 - 2 minutesmins - By Liza Laws

News and Trends 7 Sep 2022

Could COVID vaccine boosters become obsolete?

A team of researchers at Tel Aviv University in Israel has demonstrated that antibodies isolated from the immune system of recovered COVID-19 patients are effective in neutralizing all known strains of the virus, including the Delta and the Omicron variants. According to the researchers, this discovery may eliminate the need for repeated booster vaccinations and […]

September 7, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 5 Sep 2022

Synairgen to collaborate on study of patients hospitalized due to respiratory viruses

Synairgen plc is to collaborate on a University of Southampton study on acute respiratory viral infection and recovery in hospital patients. The UNIVERSAL (Understanding Infection, Viral Exacerbation and Respiratory Symptoms at Admission-Longitudinal) trial is an observational study being led by the Clinical Trials Unit of the University of Southampton in the U.K. to explore and […]

September 5, 2022 - 3 minutesmins - By Jim Cornall

covid-19 vaccine emergency use authorization

News and Trends 29 Aug 2022

AIVITA Biomedical announces publication of trial results of its COVID-19 vaccine

Safety and efficacy results from phase 1 and 2 clinical trials looking at a Covid-19 vaccine made at point-of-care by third party personnel have been published. AIVITA Biomedical Inc., a biotech specializing in cell applications, made the announcement today (August 29). The results were published in the article in the journal Human Vaccines & Immunotherapeutics. […]

August 29, 2022 - 3 minutesmins - By Liza Laws

Covid vaccine lawsuit: Moderna vs Pfizer

News and Trends 26 Aug 2022

Moderna to sue Pfizer and German partner, BioNTech, for allegedly “copying technology”

Moderna is today (August 26) filing patent infringement lawsuits against Pfizer and its partner BioNTech in both the U.S and Germany. The mRNA-focused biotech claims the companies’ Covid-19 vaccine Comirnaty infringes patents it led between 2010 and 2016 covering Moderna’s foundational mRNA technology which the company says was critical to the development of its own […]

August 26, 2022 - 4 minutesmins - By Liza Laws

More News! 24 Aug 2022

COVID-19 vaccine less sensitive to mutations being developed in Sweden

A new generation of coronavirus vaccine is being developed by Swedish researchers from the Karolinska Institutet. The vaccine is being specifically designed to be less sensitive to mutations and better equipped for any future strains. Promising results The vaccine showed promising results in mice in a newly published study in EMBO Molecular Medicine, and the researchers […]

August 24, 2022 - 3 minutesmins - By Liza Laws

News and Trends 22 Aug 2022

Ascletis is first Chinese biotech company to get IND approvals for oral RdRp inhibitor

An investigational new drug (IND) application for a COVID-19 treatment has been approved by the China National Medical Products Administration (NMPA). The application is for ASC10, an oral inhibitor drug candidate targeting RNA-dependent RNA polymerase (RdRp) that targets the COVID-19 virus. China’s first Ascletis is China’s first biotech company to obtain IND approvals of an […]

August 22, 2022 - 2 minutesmins - By Liza Laws

News and Trends 22 Aug 2022

Roche launches COVID-19 test to detect emerging variant of interest

Roche and its subsidiary TIB Molbiol have developed a COVID-19 test for researchers that detects and differentiates the latest sub-variant of interest BA.2.75. The test specifically targets two of the known unique mutations in BA.2.75, which allows clear differentiation against other notable subvariants. “Roche is pleased to have developed a test for researchers that provides […]

August 22, 2022 - 2 minutesmins - By Jim Cornall

Roche announces Xofluza approval and new Elecsys IGRA SARS-CoV-2 test

News and Trends 15 Aug 2022

Roche announces influenza drug approval and new COVID test

Roche has announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil) for the treatment of acute uncomplicated influenza in otherwise healthy children aged five to less than 12 years of age who have been symptomatic for no more than 48 hours. This marks […]

August 15, 2022 - 6 minutesmins - By Jim Cornall

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us